Retatrutide: What the Research Actually Shows

Retatrutide is one of the newest compounds in the metabolic category, and it already has real human clinical-trial data behind it. This page walks through what researchers have studied, in plain language, so you can read the science for yourself.

A quick note on framing. Retatrutide (also called LY3437943) is a lab-made molecule that switches on three hormone receptors at once. It is still investigational and carries no approval for any use. We cite the trial literature below as research, not as a suggestion to use anything.

What researchers have studied

Phase 2 obesity trial, 338 adults (Jastreboff, NEJM, 2023). A randomized, placebo-controlled trial. Adults with obesity or overweight received weekly retatrutide at doses up to 12 mg for 48 weeks. Researchers recorded an average body-weight change of about -24% in the 12 mg group at 48 weeks, compared with about -2% on placebo. The most common events logged were gastrointestinal, mostly mild to moderate, and tied to dose. PMID 37366315. https://pubmed.ncbi.nlm.nih.gov/37366315/

Phase 2 type 2 diabetes trial, 281 adults (Rosenstock, Lancet, 2023). A randomized trial with both a placebo group and an active comparator (dulaglutide). Over 36 weeks, researchers measured drops in HbA1c (a long-term blood-sugar marker) of around 2 points at the higher doses, along with body-weight reductions near 17%, within the studied group. PMID 37385280. https://pubmed.ncbi.nlm.nih.gov/37385280/

Phase 2a liver-fat trial, 98 participants (Sanyal, Nature Medicine, 2024). A randomized, placebo-controlled trial in adults with metabolic-associated fatty liver disease. Researchers measured liver fat by MRI. In the 12 mg group, liver fat fell about 82% at 24 weeks versus almost no change on placebo, and more than 85% of that group reached a normal liver-fat level inside the study. PMID 38858523. https://pubmed.ncbi.nlm.nih.gov/38858523/

Trial registry record (ClinicalTrials.gov). The phase 2 obesity study is registered as NCT04881760, with the full protocol, dosing schedule, and outcome measures on file. https://clinicaltrials.gov/study/NCT04881760

How it works

Most weight-and-metabolism compounds you have heard of hit one or two gut-hormone signals. Retatrutide is built to act on three at once: GLP-1, GIP, and glucagon.

In plain terms, GLP-1 and GIP are signals tied to appetite and blood sugar. Glucagon is a signal tied to how the body burns stored energy. Researchers designed retatrutide to switch on all three receptors together. The idea studied in the trials above is that hitting the glucagon receptor, on top of the other two, may raise energy use while the GLP-1 and GIP arms work on appetite and blood sugar.

That third target is what sets it apart from the older single and double agonists. Researchers are still mapping exactly how the three signals balance out.

What the research does not establish

Read this part twice. The honest limits matter more than the headlines.

• Retatrutide is investigational. It is not approved for any use, and it has not been shown to be effective or safe in general use.
• The human trials so far are phase 2, meaning mid-stage. They ran under 12 months in specific groups (obesity, type 2 diabetes, fatty liver). They do not establish long-term outcomes or results in the general public.
• The trials logged side effects, mostly gastrointestinal, within their groups. That record is not a statement about safety for any one person, and nothing here is a claim that this compound is safe to use.
• Every number above describes what happened in a research model. It does not tell you what would happen in a person, and it does not say the compound does anything “for you.”

For Research Use Only. Not for human consumption. Etched Research supplies compounds for laboratory and research use only. Independent identity and purity testing by Janoshik. Nothing on this page is medical advice, a health claim, or a recommendation to use.